Iranian Society of Gynecology Oncology


1 Department of Obstetrics and Gynecology, Imam Khomeini Hospital, Tehran, Iran

2 Department of Obstetrics and Gynecology, Valiasr Hospital, Tehran University of Medical Sciences, Tehran, Iran

3 Valiasr Hospital, Tehran University of Medical Sciences, Tehran, Iran

4 Department of Physiotherapy, Faculty of Rehabilitation Sciences, Shahid Beheshti University of Medical Sciences, Damavand, Tehran, Iran


Background: Urgency is a characteristic for overactive bladder and is defined by a sudden obligatory need for urination, a feeling that can be hardly stopped. Many methods such as drug therapy and feedback have been used to treat urinary incontinency.
Objectives: The aim of this study was to assess and compare the effect of medication, biofeedback or biofeedback plus medication on urge- urinary incontinency and quality of life of patients.
Methods: This was a case-control randomized clinical trial performed on patients referred to Imam Khomeini hospital in 2014. Patients were divided into three groups of drug (Tolterodine), biofeedback, and biofeedback plus drug. Biofeedback group underwent two sessions of treatment weekly for four weeks, and the drug group received tolterodine (4 mg slow release) for four weeks. The third group received both of them. Quality of life and urinary incontinency symptoms were compared between the three groups and analyzed, using SPSS Version 16 software (IBM, Armonk, USA).
Results: Meaningful differences were observed between the three groups with respect to change in the total score of the questionnaire (P < 0.001). Between the groups, drug therapy had the most effect on improving the total score of the questionnaire, with a mean change of 25.44 ± 1.80. No meaningful difference was observed between drug plus biofeedback and biofeedback group (P =0.114). By comparing the mean incontinency score, we found a meaningful difference between the drug and biofeedback groups and the biofeedback and biofeedback plus drug groups (P < 0.001 and P < 0.002, respectively); however, no meaningful difference was found between the biofeedback plus drug group and the drug group in mean incontinency score (P = 0.187).
Conclusions: Our study results revealed that tolterodine and biofeedback both increased quality of life indices and decreased the severity of urinary incontinency significantly in our participants. However, drug plus biofeedback treatment improved the severity and quality of urinary incontinency, but did not improve quality of life of the patients. Therefore, physicians should consider improving the quality of life of patients as well.


  1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167-78. [DOI:10.1002/nau.10052]
  2. Kinder RB, Mundy AR. Pathophysiology of idiopathic detrusor instability and detrusor hyper-reflexia. An in vitro study of human detrusor muscle. Br J Urol. 1987;60(6):509-15. [DOI:10.1111/j.1464-410X.1987.tb05031.x]
  3. Patel AK, Chapple CR. Urodynamics in the management of female stress incontinence-which test and when?. Curr Opin Urol. 2008;18(4):359-64. [DOI:10.1097/MOU.0b013e3283023c0e]
  4. Curtis LA, Dolan TS, Cespedes RD. Acute urinary retention and urinary incontinence. Emerg Med Clin North Am. 2001;19(3):591-619. [DOI:10.1016/S0733-8627(05)70205-4]
  5. Cummings JM, Rodning CB. Urinary stress incontinence among obese women: review of pathophysiology therapy. Int Urogynecol J Pelvic Floor Dysfunct. 2000;11(1):41-4. [DOI:10.1007/s001920050008]
  6. Sustersic O, Kralj B. The influence of obesity, constitution and physical work on the phenomenon of urinary incontinence in women. Int Urogynecol J Pelvic Floor Dysfunct. 1998;9(3):140-4. [DOI:10.1007/BF02001082]
  7. DuBeau CE. Interpreting the effect of common medical conditions on voiding dysfunction in the elderly. Urol Clin North Am. 1996;23(1):11-8. [DOI:10.1016/S0094-0143(05)70289-5]
  8. American Urological Association . Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guidelines. ;2013. [DOI:10.1016/j.yuro.2013.02.008]
  9. Dmochowski RR. Treatment of the overactive bladder: where we stand in 2003. Rev Urol. 2003;5 Suppl 8:S11-7.
  10. Kirby M, Artibani W, Cardozo L, Chapple C, Diaz DC, De Ridder D, et al. Overactive bladder: The importance of new guidance. Int J Clin Pract. 2006;60(10):1263-71. [DOI:10.1111/j.1742-1241.2006.01127.x]
  11. Lai HH, Boone TB, Appell RA. Selecting a medical therapy for overactive bladder. Rev Urol. 2002;4 Suppl 4:S28-37.
  12. Lee M, Weberski J. Options for treatment of overactive bladder. J Am Pharm Assoc. 2005:1-15.
  13. Ouslander JG. Management of overactive bladder. N Engl J Med. 2004;350(8):786-99. [DOI:10.1056/NEJMra032662]
  14. Brown T. Overactive bladder guidelines released. Medscape Medical News; 2012.
  15. Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2012;188(6 Suppl):2455-63. [DOI:10.1016/j.juro.2012.09.079]
  16. Alhasso AA, McKinlay J, Patrick K, Stewart L. Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2006(4):CD003193. [DOI:10.1002/14651858.CD003193.pub3]
  17. Lackner TE. Pharmacotherapy of urinary incontinence. J Am Med Dir Assoc. 2002;3(1 Suppl):S16-24. [DOI:10.1016/S1525-8610(04)70254-6]
  18. Staskin DR. Trospium chloride: Distinct among other anticholinergic agents available for the treatment of overactive bladder. Urol Clin North Am. 2006;33(4):465-73. [DOI:10.1016/j.ucl.2006.06.006]
  19. Zinner NR. Trospium chloride: an anticholinergic quaternary ammonium compound for the treatment of overactive bladder. Expert Opin Pharmacother. 2005;6(8):1409-20. [DOI:10.1517/14656566.6.8.1409]
  20. Brunton S, Kuritzky L. Recent developments in the management of overactive bladder: focus on the efficacy and tolerability of once daily solifenacin succinate 5 mg. Curr Med Res Opin. 2005;21(1):71-80. [DOI:10.1185/030079904X20268]
  21. Kelleher CJ, Cardozo L, Chapple CR, Haab F, Ridder AM. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int. 2005;95(1):81-5. [DOI:10.1111/j.1464-410X.2004.05255.x]
  22. Maniscalco M, Singh-Franco D, Wolowich WR, Torres-Colon R. Solifenacin succinate for the treatment of symptoms of overactive bladder. Clin Ther. 2006;28(9):1247-72. [DOI:10.1016/j.clinthera.2006.09.017]
  23. Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother. 2006;4(1):14-24. [DOI:10.1016/j.amjopharm.2006.03.004]
  24. Zinner N, Susset J, Gittelman M, Arguinzoniz M, Rekeda L, Haab F. Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. Int J Clin Pract. 2006;60(1):119-26. [DOI:10.1111/j.1368-5031.2005.00770.x]
  25. Tapp AJ, Cardozo LD, Versi E, Cooper D. The treatment of detrusor instability in post-menopausal women with oxybutynin chloride: a double blind placebo controlled study. Br J Obstet Gynaecol. 1990;97(6):521-6. [DOI:10.1111/j.1471-0528.1990.tb02523.x]
  26. Abrams P. Evidence for the efficacy and safety of tolterodine in the treatment of overactive bladder. Expert Opin Pharmacother. 2001;2(10):1685-701. doi: 10.1517/14656566.2.10.1685. [DOI:10.1517/14656566.2.10.1685]
  27. Kanofsky JA, Nitti VW. Tolterodine for treatment of overactive bladder. Urol Clin North Am. 2006;33(4):447-53. [DOI:10.1016/j.ucl.2006.06.004]
  28. Wilson PD, Berghmans B, Hagen S. In: Incontinence Management. Abrams P, Cardozo L, Khoury S, Wein A, editors. Paris, France: Health Publications; 2005. pp. 855-94.Adult conservative management.
  29. Kafri R, Deutscher D, Shames J, Golombp J, Melzer I. Randomized trial of a comparison of rehabilitation or drug therapy for urgency urinary incontinence: 1-year follow-up. Int Urogynecol J. 2013;24(7):1181-9. [DOI:10.1007/s00192-012-1992-8]
  30. Ghanbari Z, Esmaili M, Eftekhar T, Esmaili M, Miri E. Comparing the efficacy and adverse effects of Oxybutinine and Tolterodine for the treatment of overactive bladder. Med Faculty J Tehran Univ Med Sci. 2011;69(5):302-8.
  31. Kashanian M, Shahali S, Nazemi M, Bahasadri S. Comparing the effect of using kegelmaster device and kegel exercise on urinary incontinency of women of reproductive age. J Iran Univ Med Sci. 2010;17(77).
  32. Wang AC. Bladder-sphincter biofeedback as treatment of detrusor in stability in women who failed to respond to oxybutynin. Chang Gung Med J. 2000;23(10):590-9.
  33. Wang AC, Wang YY, Chen MC. Single-blind, randomized trial of pelvic floor muscle training, biofeedback-assisted pelvic floor muscle training, and electrical stimulation in the management of overactive bladder. Urology. 2004;63(1):61-6. [DOI:10.1016/j.urology.2003.08.047]
  34. Hirakawa T, Suzuki S, Kato K, Gotoh M, Yoshikawa Y. Randomized controlled trial of pelvic floor muscle training with or without biofeed back for urinary incontinence. Int Urogynecol J. 2013;24(8):1347-54. [DOI:10.1007/s00192-012-2012-8]